why choose us

Clinical Trials Search

Showing 14,330 of 132,963 result(s)
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase II;III

Status: NOT_YET_RECRUITING

Condition: Retinitis Pigmentosa

Interventions: 1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Date: 2023-03-14

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Status: Completed

Condition: Elevated Low-Density Lipoprotein Cholesterol

Interventions: A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.

Date: 2023-03-14

Hemorrhagic Complications of Transvaginal Oocyte's Retrieval: an Update.

Status: COMPLETED

Condition: ART

Interventions:

Date: 2023-03-14

Diet Interventions, by Race, Evaluated as Complementary Treatments for Pain

Status: Completed

Condition: Knee Osteoarthritis

Interventions: A 6 week randomized diet low in carbohydrates

Date: 2023-03-14

FLUME Catheter Comfort Study

Status: Completed

Condition: Urinary Catheters

Interventions:

Date: 2023-03-14

A Study of DB-1310 in Advanced;Metastatic Solid Tumors

Status: Completed

Condition: Advanced Solid Tumor

Interventions: Administered I.V.

Date: 2023-03-14

ENDOblock: Bilateral Superficial Cervical Blocks With Local Wound Infiltration in Thyroid Surgery

Status: Completed

Condition: Post Operative Pain

Interventions: 10mL bupivacaine at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision

Date: 2023-03-14

Advancing Couple and Family Alcohol Treatment Through Patient-Oriented Research and Mentorship

Status: Completed

Condition: Alcohol Use Disorder

Interventions: Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g;dL BrAC)

Date: 2023-03-14

A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Status: Completed

Condition: Type 2 Diabetes Treated With Insulin

Interventions: The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional featur

Date: 2023-03-14

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Status: Completed

Condition: Adenoid Cystic Carcinoma

Interventions: First-in-class pan-NOTCH inhibitor, capsule taken orally.

Date: 2023-03-14